美诺华：全资子公司获得非布司他片药品注册证书

Core Viewpoint - The company Menohua has received approval from the National Medical Products Administration for its subsidiary Ningbo Menohua Tiankang Pharmaceutical Co., Ltd. to market Febuxostat tablets for the long-term treatment of hyperuricemia in gout patients [1] Group 1: Product Approval - The approved product is Febuxostat tablets, available in dosages of 20mg and 40mg [1] - The registration classification for the drug is classified as a Class 4 chemical drug [1] - The approval numbers for the drug are National Drug Approval Number H20256169 and H20256168, with a validity period until December 2, 2030 [1] Group 2: Indication and Usage - The drug is indicated for the long-term treatment of hyperuricemia in patients with gout [1]